AstraZeneca (AZN) has released an update.
AstraZeneca PLC’s drug Truqap, in combination with Faslodex, has been recommended for EU approval for treating advanced ER-positive breast cancer with certain biomarker alterations, after showing a 50% reduction in disease progression or death. This recommendation is based on the CAPItello-291 Phase III trial results, potentially offering a new treatment option for these patients. Regulatory applications for this combination are currently under review in China and other countries, with approvals already in place in Japan, the US, and several others.
For further insights into AZN stock, check out TipRanks’ Stock Analysis page.
